Charting Our Path Forward:
The Mission and Vision of Our Company
Baioflow:
Meeting the Rising Demand for Advanced Drug Delivery
In today’s drug development market, pharmaceutical companies are increasingly seeking innovative drug delivery strategies.
While technologies such as transferrin (TfR)-based approaches have led to licensing deals, challenges remain — including patent constraints, limited performance, and restricted applicability.
As real-world applications begin to emerge, demand for effective delivery solutions is surging across the industry.
Securing a reliable delivery system is no longer optional but essential, with many companies accelerating adoption as proven use cases continue to grow.
Baioflow addresses this need through its Bio-Intelligence platform, which discovers organ-crossing enhancers (OCEs) by combining real biological data with AI — overcoming the BBB and other organ barriers.
Through collaborative projects with global partners, Baioflow is demonstrating how its platform can be applied to discover novel delivery vehicles and enable next-generation therapies.
Baioflow goes beyond prediction — we create tangible value through real-world collaboration and application.
Team of Specialists
Founding CEO
Daehoon Kim
Biotech & AI-Driven Drug Discovery Executive
Ph.D., Hokkaido University
Daehoon Kim is the founding CEO of Baioflow and a biotech leader with cross-disciplinary expertise in biology and AI-driven drug discovery. He has more than 15 years of experience spanning experimental biology, computational platforms, and translational drug development.
He has led global R&D initiatives at innovative biotech organizations, directing programs from early target discovery to preclinical development. His experience covers AI/ML drug discovery platforms, RNA and gene therapy, and CNS-targeted delivery systems. By combining bioinformatics, molecular biology, and data science, he has built integrated R&D pipelines that bridge computational prediction with experimental validation.
Dr. Kim has successfully managed early discovery through IND-enabling studies, secured multiple national research grants, and conducted collaborative research and technical due diligence with global pharmaceutical partners. His leadership also includes building and guiding cross-functional teams across diverse therapeutic modalities, ranging from oncology to neurological disorders.
At Baioflow, he combines this dual expertise in biology and AI to advance the company’s Bio-Intelligence platform, pioneering the discovery of organ-crossing enhancers (OCEs). His vision is to transform CNS and organ-targeted drug development by uniting real experimental bio-data with advanced AI, creating a new paradigm in therapeutic delivery.
CTO
Hyunsu Min
Drug Delivery Systems & Brain Target Delivery Expert
Ph.D., Korea University
Dr. Hyunsu Min, CTO of Baioflow, is an expert in drug delivery systems and brain-targeted delivery with extensive research and development experience.
While AI can identify potential organ-crossing enhancer (OCE) candidates, transforming them into functional delivery systems requires deep expertise in pharmacology and formulation.
With this expertise, he addresses the complex challenge of translating predictive AI into real therapeutic applications, turning BaioAI™ predictions into practical carriers that cross the BBB and other organ barriers.
He has developed stable RNA platforms through oligo-modification, led collaborations with external partners on joint research and feasibility assessments for technology transfer, and managed multi-disciplinary teams advancing CNS-targeted delivery programs.His research background includes postdoctoral work in Japan on nanoparticle-based siRNA and ASO delivery across the BBB, as well as doctoral training in theranostic nanoparticles and multifunctional polymers for drug delivery.
At Baioflow, Dr. Min applies this expertise to ensure that the Bio-Intelligence platform not only generates predictions but also delivers tangible therapeutic solutions for CNS and organ-targeted diseases.
Head of Bio Div.
Yuna Lim
Chemistry & Brain Target Delivery Expert
Ph.D., Ajou University
Drug discovery requires seamless integration of chemistry and biology. While AI can generate predictions, validating and optimizing them demands deep expertise in molecular design and experimental biology.
As Head of the Bio Division, Dr. Lim provides this essential link. With strong expertise in chemistry and brain-targeted delivery systems, she designs and optimizes molecules predicted by BaioAI™, and ensures their biological relevance through in vitro, ex vivo, and in vivo validation. Her leadership guarantees that Baioflow’s Bio-Intelligence platform moves beyond theory into real, validated drug delivery solutions.
Her expertise spans the design and synthesis of organ-targeted molecules and transporters, the development of delivery systems including novel nanoparticles for RNA and small-molecule therapeutics, and RNA molecule design, synthesis, encapsulation, and evaluation. She has led multi-disciplinary teams advancing CNS-targeted drug discovery platforms and managed collaborative research with academic and industrial partners.
Dr. Lim has authored over 10 scientific publications in journals including Molecular Therapy – Nucleic Acids, ACS Macro Letters, Applied Organometallic Chemistry, Industrial & Engineering Chemistry Research, ACS Sustainable Chemistry & Engineering, European Journal of Organic Chemistry, and RSC Advances.
Company's Mission & Vision
Pursuing Bio × AI Integration
Building a Bio-Intelligence platform where biology and AI converge — powered by real bio-data.
Breaking Barriers in Drug Delivery
Developing organ-crossing enhancers (OCEs) that overcome the BBB and other organ barriers to enable targeted therapies.
Unlocking New Modalities
Applying Bio-Intelligence to discover novel delivery solutions for peptides, biologics, and ADCs.
Global Collaboration Driven
Partnering with biotech, pharma, and academia to co-develop CNS and organ-specific therapies worldwide.
The Journey of Baioflow
Baioflow was founded with the mission of showing how biology and AI can be truly integrated in drug discovery.
By combining real bio-data with advanced AI, we are building a Bio-Intelligence platform that discovers validated organ-crossing enhancers (OCEs) for targeted delivery.
Our goal is to demonstrate, through real-world evidence, that the fusion of biology and AI can overcome barriers and transform the way therapies are developed.
By combining real bio-data with advanced AI, we are building a Bio-Intelligence platform that discovers validated organ-crossing enhancers (OCEs) for targeted delivery.
Our goal is to demonstrate, through real-world evidence, that the fusion of biology and AI can overcome barriers and transform the way therapies are developed.